UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of June 2015
001-37353
(Commission File Number)
BIONDVAX PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in its charter)
14 Einstein St.
Ness Ziona
Israel 74036
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No þ
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A
Below is an English translation (from Hebrew) from an immediate report by BiondVax Pharmaceuticals Ltd. (the "Company") as published on the Tel-Aviv Stock Exchange Ltd. ("TASE") and the Israeli Securities Authority ("ISA") on June 22, 2015, in accordance with the Israeli Securities Regulations.
The Company announces that on June 22, 2015, the Company's amount of securities was updated to reflect the following change:
Description of the nature of the change:allocation of ordinary shares in accordance with an additional and partial exercise of the Underwriter's over-allotment option in connection with the initial public offering in the U.S. (see immediate report of the Company dated June 21, 2015, reference no. 2015-01-052110)
The name of holder following the allocation: Bank Leumi Le-Israel Registration Company Ltd.
Type of identification Number: Israeli Companies registrar no.: 510098064
Nature of Change: Initial Public Offering
Date of Change: June 22, 2015
Class of Securities and TASE number: ordinary shares NIS 0.0000001 par value each, TASE no. 1105204
Amount of Securities: 4,400,000
Total amount of Securities held by the holder: 134,915,327
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BiondVax Pharmaceuticals Ltd. | ||
| Date: June 23, 2015 | By: | /s/ Ron Babecoff |
| Ron Babecoff | ||
| Chief Executive Officer | ||
3